medigraphic.com

2022, Number 3

<< Back Next >>

Enf Infec Microbiol 2022; 42 (3)

Monkeypox what should we know?

Ángel AAH, Mondragón SDL, Bautista CP, Villanueva TLF, Morales FJA, Pérez ADM, García LML, Navarrete HL, Fragoso GMB, Cortázar MLA, Vite VX, Martínez RR, Ortega MJB, Trujillo GLD, Valadez GY, Vásquez MLM, Díaz RJB, Wong CRM

Language: Spanish
References: 39
Page: 115-120
PDF size: 198.41 Kb.


ABSTRACT

Monkeypox caused by the monkeypox virus (MPXV) is rare outside of Africa. However, by August 2022 there are at least 78 affected countries with more than 19 000 cases. The clinical manifestations are fever, chills, fatigue, headache, muscle pain, sore throat, lymphadenopathy and skin lesions from macules, pustules to scabs lasting two to three weeks and are self-limited. Although single anogenital lesions have been reported in the current outbreak. Diagnosis is clinical, by laboratory using viral culture, immunohistochemistry, ELISA and PCR. Treatment is symptomatic. Some approved drugs are tecovirimat, cidofovir, and intravenous anti-vaccinia immunoglobulin. There are two licensed vaccines in the United States to prevent smallpox, ACAM2000 and JYNNEOS. The risk to the world population is considered moderate. The sudden onset and wide geographic scale indicate that person-to-person transmission is underway.


REFERENCES

  1. Monkeypox|Poxvirus|cdc, 2022. Disponible en: https://www.cdc.gov/poxvirus/monkeypox/index.html. Consultadoel 17 de junio de 2022).

  2. Marennikova, S.S. y Šeluhina, E.M., “Susceptibility of somerodent species to monkeypox virus, and course ofthe infection”, Bull World Health Organ, 1976, 53: 13-20.

  3. Cho, C.T. y Wenner, H.A., “Monkeypox virus”, BacteriolRev, 1973, 37: 1-18.

  4. Sklenovská, N. y Van Ranst, M., “Emergence ofmonkeypox as the most important orthopoxvirus infectionin humans”, Front Public Health, 2018, 6: 241.

  5. Centers for Disease Control and Prevention (cdc), “Multistateoutbreak of monkeypox: Illinois, Indiana, andWisconsin”, 2003, mmwr Morb Mortal Wkly Rep, 2003,52: 537-540.

  6. Erez, N., Achdout, H., Milrot, E., Schwartz, Y., Wiener-Well, Y., Paran, N. et al., “Diagnosis of importedmonkeypox, Israel, 2018”, Emerg Infect Dis, 2019, 25:980-983.

  7. Hobson, G., Adamson, J., Adler, H., Firth, R., Gould,S., Houlihan, C. et al., “Family cluster of three cases ofmonkeypox imported from Nigeria to the United Kingdom,May 2021”, Euro Surveill Bull Eur Sur Mal TransmEur Commun Dis Bull, 2021, 26. doi: 10.2807/1560-7917.ES.2021.26.32.2100745.

  8. “Monkeypox: United Kingdom of Great Britain andNorthern Ireland”. Disponible en: https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON383. Consultado el 4 de agosto de 2022.

  9. “Multi-country monkeypox outbreak in non-endemiccountries: Update”. Disponible en: https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON388. Consultado el 4 de agosto de 2022.

  10. “Monkeypox”. Disponible en: https://www.who.int/emergencies/emergency-events/item/2022-e000121.Consultado el 4 de agosto de 2022.

  11. “who Director-General’s statement at the press conferencefollowing ihr Emergency Committee regar-ding the multi-country outbreak of monkeypox, 23July 2022”. Disponible en: https://www.who.int/director-general/speeches/detail/who-director-general-s-statement-on-the-press-conference-following-IHR-emergency-committee-regarding-the-multi--country-outbreak-of-monkeypox--23-july-2022.Consultado el 4 de agosto de 2022.

  12. “Taxonomy history, taxonomy, ictv”. Disponible en: https://talk.ictvonline.org/taxonomy/p/taxonomy-history?-taxnode_id=20174771. Consultado el 9 de junio de2022.

  13. Moss, B., “Poxvirus dna replication”, Cold Spring HarbPerspect Biol, 2013, 5: a010199.

  14. Animal-origin viral zoonoses. Disponible en: https://link.springer.com/book/10.1007/978-981-15-2651-0. Consultadoel 9 de junio de 2022.

  15. Resch, W., Hixson, K.K., Moore, R.J., Lipton, M.S. yMoss, B., “Protein composition of the vaccinia virus maturevirion”, Virology, 2007, 358: 233-247.

  16. Geshelin, P. y Berns, K.I., “Characterization and localizationof the naturally occurring cross-links in vacciniavirus dna”, J Mol Biol, 1974, 88: 785-796.

  17. Baroudy, B.M., Venkatesan, S. y Moss, B., “Incompletelybase-paired flip-flop terminal loops link the two dnastrands of the vaccinia virus genome into one uninterruptedpolynucleotide chain”, Cell, 1982, 28: 315-324.

  18. Shchelkunov, S.N., Totmenin, A.V., Babkin, I.V., Safronov,P.F., Ryazankina, O.I., Petrov, N.A. et al., “Humanmonkeypox and smallpox viruses: genomic comparison”,febs Lett, 2001, 509: 66-70.

  19. Bahar, M.W., Graham, S.C., Chen, R.A.J, Cooray, S.,Smith, G.L., Stuart, D.I. et al., “How vaccinia virus hasevolved to subvert the host immune response”, J StructBiol, 2011, 175: 127-134.

  20. Buller, R.M. y Palumbo, G.J., “Poxvirus pathogenesis”,Microbiol Rev, 1991, 55: 80-122.

  21. Moss, B., “Membrane fusion during poxvirus entry”,Semin Cell Dev Biol, 2016, 60: 89-96.

  22. Sklenovská, N., “Monkeypox virus”. En Malik, Y.S., Singh,R.K. y Dhama, K. (eds)., Animal-origin viral zoonoses,Singapur, Springer, 2020, pp. 39-68.

  23. Guarner, J., Del Río, C. y Malani, P.N., “Monkeypox in2022: what clinicians need to know?, jama, 2022. doi:10.1001/jama.2022.10802.

  24. Thornhill, J.P., Barkati, S., Walmsley, S., Rockstroh, J.,Antinori, A., Harrison, L.B. et al., “Monkeypox virus infectionin humans across 16 countries: April-June 2022”, NEngl J Med, 2022. doi: 10.1056/NEJMoa2207323.

  25. Walter, K. y Malani, P.N., “What is monkeypox?”, jama,2022. doi: 10.1001/jama.2022.10259.

  26. Grant, R., Nguyen, L.B.L. y Breban, R., “Modelling human-to-human transmission of monkeypox”, Bull WorldHealth Organ, 2020, 98: 638-640.

  27. Kabuga, A.I. y El Zowalaty, M.E., “A review of themonkeypox virus and a recent outbreak of skin rash diseasein Nigeria”, J Med Virol, 2019, 91: 533-540.

  28. Gobierno de México, Secretaría de Salud, “Guía para elmanejo médico de los casos de viruela símica en México,2022”, 2022. Disponible en: chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://viruela.salud.gob.mx/docs/2022.07.25_AbordajeViruelaSimica.pdf.

  29. “Interim clinical guidance for the treatment ofmonkeypox|monkeypox|poxvirus|cdc”, 2022. Disponibleen: https://www.cdc.gov/poxvirus/monkeypox/treatment.html. Consultado el 17 de junio de 2022.

  30. Russo, A.T., Grosenbach, D.W., Chinsangaram, J.,Honeychurch, K.M., Long, P.G., Lovejoy, C. et al., “Anoverview of tecovirimat for smallpox treatment andexpanded anti-orthopoxvirus applications”, Expert RevAnti Infect Ther, 2021, 19: 331-344.

  31. Rizk, J.G., Lippi, G., Henry, B.M., Forthal, D.N. y Rizk,Y., “Prevention and treatment of monkeypox”, Drugs,2022, 82: 957-963.

  32. “Multi-country monkeypox outbreak: situation update”.Disponible en: https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON396. Consultadoel 4 de agosto de 2022.

  33. “Research c for be and acam2000 (smallpox vaccine)questions and answers”, fda, 2021. Disponible en: https://www.fda.gov/vaccines-blood-biologics/vaccines/acam2000-smallpox-vaccine-questions-and-answers.Consultado el 5 de agosto de 2022.

  34. “Research c for be and jynneos”, fda, 2021. Disponibleen: https://www.fda.gov/vaccines-blood-biologics/jynneos.Consultado el 5 de agosto de 2022.

  35. “Monkeypox and smallpox vaccine guidance|-monkeypox|poxvirus|cdc”, 2022. Disponible en: https://www.cdc.gov/poxvirus/monkeypox/clinicians/smallpox-vaccine.html. Consultado el 14 de junio de 2022.“Multi-country monkeypox outbreak: situation update”.

  36. Disponible en: https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON392. Consultadoel 17 de junio de 2022.Patel, A., Bilinska, J., Tam, J.C.H., Da Silva Fontoura, D.,

  37. Mason, C.Y., Daunt, A., Snell, L.B., Murphy, J., Potter, J.,Tuudah, C., Sundramoorthi, R., Abeywickrema, M., Pley,C., Naidu, V., Nebbia, G., Aarons, E., Botgros, A., Douthwaite,S.T., Van Nispen, T., Pannerden, C., Winslow,H., Brown, A., Chilton, D. y Nori, A., “Clinical featuresand novel presentations of human monkeypox in a centralLondon centre during the 2022 outbreak: descriptivecase series”, bmj, 2022, 378: e072410.Thornhill, J.P., Barkati, S., Walmsley, S., Rockstroh, J.,

  38. Antinori, A., Harrison, L.B., Palich, R., Nori, A., Reeves,I., Habibi, M.S., Apea, V., Boesecke, C., Vandekerckhove,L., Yakubovsky, M., Sendagorta, E., Blanco, J.L.,Florence, E., Moschese, D., Maltez, F.M., Goorhuis, A.,Pourcher, V., Migaud, P., Noe, S., Pintado, C., Maggi, F.,Hansen, A.E., Hoffmann, C., Lezama, J.I., Mussini, C.,Cattelan, A., Makofane, K., Tan, D., Nozza, S., Nemeth,J., Klein, M.B. y Orkin, C.M., “share-net Clinical Group.Monkeypox virus infection in humans across 16 countries:April-June 2022”, N Engl J Med, 2022.Titanji, B.K., Tegomoh, B., Nematollahi, S., Konomos,

  39. M., Kulkarni y P.A., “Monkeypox: a contemporary reviewfor healthcare professionals”, Open Forum Infect Dis,2022, 9 (7): ofac310.




2020     |     www.medigraphic.com